No abstract

Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.

No abstract

No abstract

Dear Reader, As we approach the end of 2015 and the completion of the first ever volume of Sports Medicine -Open, the editors and production staff at SpringerOpen wish to reflect on a successful year's achievements and pay thanks to all those who have contributed their time and effort to establish this new journal.We have been delighted by the way the sports science community has embraced the new journal and grateful for the number of high-quality submissions that the journal has received. The inaugural volume of Sports Medicine -Open will close with more than 20 original research articles, a dozen review articles (including systematic reviews), one particularly well-downloaded current opinion piece, and two editorials. And while we must offer our sincere thanks to all the authors who have contributed thus far, the quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that our content is held to the highest possible standard.